RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-small Cell Lung Cancer

CONCLUSIONS: RAM+ERL provided significant clinical benefit for both EGFR ex19del and ex21L858R NSCLC, supporting this regimen as suitable for patients with either of these EGFR mutation types.PMID:34301751 | DOI:10.1158/1078-0432.CCR-21-0273

Source: Clinical Cancer Research - July 24, 2021 Category: Cancer & Oncology Authors: Kazuhiko Nakagawa Ernest Nadal Edward B Garon Makoto Nishio Takashi Seto Nobuyuki Yamamoto Keunchil Park Jin-Yuan Shih Luis Paz-Ares Bente Frimodt-Moller Annamaria H Zimmermann Sameera Wijayawardana Carla Visseren-Grul Martin Reck Source Type: research